View in EDS

385TiP - RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease

Saved in:
Bibliographic Details
Title: 385TiP - RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease
Authors: Kenis, C.1 (AUTHOR), Ponde, N.F.2 (AUTHOR), Decoster, L.3 (AUTHOR), de Azambuja, E.4 (AUTHOR), Jerusalem, G.5 (AUTHOR), Neven, P.6 (AUTHOR), Dal Lago, L.7 (AUTHOR), Denys, H.8 (AUTHOR), Vuylsteke, P.9 (AUTHOR), Duhoux, F.P.10 (AUTHOR), Wildiers, H.1 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv140-v140. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz242.080